Literature DB >> 11114136

Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.

V Liso1, F Albano, D Pastore, P Carluccio, G Mele, M Lamacchia, A Mestice, G Specchia.   

Abstract

BACKGROUND AND OBJECTIVES: In adult acute myeloid leukemia (AML), a variety of clinical and biological parameters have been examined for their potential value in predicting treatment response. Early response to induction therapy could be an important prognostic factor in this disease. DESIGN AND METHODS: We studied the relationship between reduced blasts in bone marrow aspirate on the 14th day (BMA14th) of induction chemotherapy and treatment outcome in 198 adult AML patients of whom 124 were < 60 years old (group A) and 74 > or = 60 years old (group B). Receiver operating characteristic curve analysis was used to assess the prognostic performance of BMA14th. Using the percentages of blasts of < or = 22% and < or = 15% as criteria for predicting treatment outcome gave the highest accuracy in terms of sensitivity and specificity in groups A and B, respectively.
RESULTS: In group A, of 97 patients with a BMA14th < or = 22%, 77 (79%) achieved complete remission (CR), whereas of 27 patients with a BMA14th > 22%, 22 (81%) were non-responders (NR) (p < 0.0001). The test sensitivity and specificity were 93.9% and 71.4%, respectively. In group B, of 27 patients with a BMA14th < or = 15%, 18 (67%) achieved CR, whereas of 47 patients with a BMA14th >15%, 38 (81%) were NR (p = 0.0001). The test sensitivity and specificity were 66.7% and 80.9%, respectively. INTERPRETATION AND
CONCLUSIONS: Our data suggest that BMA14th may be a predictive test for CR, helping to identify NR patients early in their disease. Further studies are needed to establish the practical implications of the results of our study.

Entities:  

Mesh:

Year:  2000        PMID: 11114136

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  10 in total

1.  Bone marrow aspiration before bone marrow core biopsy using the same bone marrow biopsy needle: a good or bad practice?

Authors:  Anwarul Islam
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

2.  Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.

Authors:  V Vainstein; S A Buckley; O Shukron; E H Estey; J L Abkowitz; B L Wood; R B Walter
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

Review 3.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

Review 4.  Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Authors:  Christine M McMahon; Alexander E Perl
Journal:  Leuk Lymphoma       Date:  2018-09-20

Review 5.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.

Authors:  J M Jaso; S A Wang; J L Jorgensen; P Lin
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

6.  Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Authors:  Nicholas J Short; Christopher B Benton; Hsiang-Chun Chen; Peng Qiu; Lisa Gu; Sherry Pierce; Mark Brandt; Abhishek Maiti; Taejin L Min; Kiran Naqvi; Alfonso Quintas-Cardama; Marina Konopleva; Tapan Kadia; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Elias Jabbour; Hagop Kantarjian; Michael Andreeff
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

7.  Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Authors:  Nicholas J Short; Hagop M Kantarjian; Koji Sasaki; Jorge E Cortes; Farhad Ravandi; Deborah A Thomas; Guillermo Garcia-Manero; Issa Khouri; Partow Kebriaei; Richard E Champlin; Sherry Pierce; Ghayas C Issa; Marina Konopleva; Tapan M Kadia; Carlos Bueso-Ramos; Joseph D Khoury; Nitin Jain; Susan M O'Brien; Elias Jabbour
Journal:  Cancer       Date:  2016-08-10       Impact factor: 6.860

Review 8.  A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination.

Authors:  Roger S Riley; Thomas F Hogan; Dawn R Pavot; Robert Forysthe; Davis Massey; Eileen Smith; Lou Wright; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

9.  Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.

Authors:  Sarah Bertoli; Pierre Bories; Marie C Béné; Sylvie Daliphard; Bruno Lioure; Arnaud Pigneux; Norbert Vey; Jacques Delaunay; Vincent Leymarie; Isabelle Luquet; Odile Blanchet; Pascale Cornillet-Lefebvre; Mathilde Hunault; Didier Bouscary; Nathalie Fegueux; Philippe Guardiola; François Dreyfus; Jean Luc Harousseau; Jean Yves Cahn; Norbert Ifrah; Christian Récher
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

10.  Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.

Authors:  João Tadeu D Souto Filho; Monique M Loureiro; Wolmar Pulcheri; José Carlos Morais; Marcio Nucci; Rodrigo D Portugal
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.